Christina Atchison
Overview
Explore the profile of Christina Atchison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1366
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raja A, Nicholls G, Coldwell M, van Veldhoven K, Sandys V, Atkinson B, et al.
Sci Rep
. 2024 Apr;
14(1):9561.
PMID: 38671031
An outbreak of SARS-CoV-2 (1 March to 10 May 2021) with an attack rate of 26.5% among approximately 1150 workers at a storage and distribution centre in England prompted a...
2.
Coukan F, Sullivan A, Mitchell H, Jaffer S, Williams A, Saunders J, et al.
Sex Transm Infect
. 2024 Mar;
100(3):166-172.
PMID: 38508708
Objectives: HIV pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV acquisition. In England, NHS availability was limited to participants of the PrEP Impact Trial until late 2020. Some key...
3.
Hampshire A, Azor A, Atchison C, Trender W, Hellyer P, Giunchiglia V, et al.
N Engl J Med
. 2024 Feb;
390(9):806-818.
PMID: 38416429
Background: Cognitive symptoms after coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are well-recognized. Whether objectively measurable cognitive deficits exist and how long...
4.
Ward H, Atchison C, Whitaker M, Davies B, Ashby D, Darzi A, et al.
Am J Public Health
. 2023 Sep;
113(11):1201-1209.
PMID: 37733993
The UK Department of Health and Social Care funded the REal-time Assessment of Community Transmission-2 (REACT-2) study to estimate community prevalence of SARS-CoV-2 IgG (immunoglobulin G) antibodies in England. We...
5.
Whitaker M, Davies B, Atchison C, Barclay W, Ashby D, Darzi A, et al.
Nat Commun
. 2023 Aug;
14(1):4957.
PMID: 37587102
The value of SARS-CoV-2 lateral flow immunoassay (LFIA) tests for estimating individual disease risk is unclear. The REACT-2 study in England, UK, obtained self-administered SARS-CoV-2 LFIA test results from 361,801...
6.
Graham A, Raja A, van Veldhoven K, Nicholls G, Simpson A, Atkinson B, et al.
BMC Public Health
. 2023 Jun;
23(1):1077.
PMID: 37277762
Background: A SARS-CoV-2 outbreak with an attack rate of 14.3% was reported at a plastics manufacturing plant in England. Methods: Between 23 March and 13 May 2021, the COVID-OUT team...
7.
Eales O, Haw D, Wang H, Atchison C, Ashby D, Cooke G, et al.
PLoS Biol
. 2023 May;
21(5):e3002118.
PMID: 37228015
The relationship between prevalence of infection and severe outcomes such as hospitalisation and death changed over the course of the COVID-19 pandemic. Reliable estimates of the infection fatality ratio (IFR)...
8.
Coukan F, Murray K, Papageorgiou V, Lound A, Saunders J, Atchison C, et al.
HIV Med
. 2023 Apr;
24(8):893-913.
PMID: 37078101
Objectives: HIV pre-exposure prophylaxis (PrEP) delivery in the UK is inequitable; over 95% of PrEP users were men who have sex with men (MSM) despite making up less than 50%...
9.
Elliott P, Whitaker M, Tang D, Eales O, Steyn N, Bodinier B, et al.
Am J Public Health
. 2023 Mar;
113(5):545-554.
PMID: 36893367
The REal-time Assessment of Community Transmission-1 (REACT-1) Study was funded by the Department of Health and Social Care in England to provide reliable and timely estimates of prevalence of severe...
10.
Eales O, Page A, Tang S, Walters C, Wang H, Haw D, et al.
Microb Genom
. 2023 Feb;
9(2).
PMID: 36745545
Genomic surveillance for SARS-CoV-2 lineages informs our understanding of possible future changes in transmissibility and vaccine efficacy and will be a high priority for public health for the foreseeable future....